News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Diatron Present Latest Clinical Chemistry Analyzer



11/14/2012 12:04:39 PM

BUDAPEST, HUNGARY (November 14, 2012): The Diatron Group, global provider of hematology and clinical chemistry analyzers, has developed its latest clinical chemistry analyzer, the Pictus 700, as a fully-automated, random-access system, suitable for today’s modern laboratory. The rapid and reliable analyzer can carry out up to 720 tests per hour, on sample volumes ranging from 0.2 µL to 100 µL, by employing continuous sample loading in a 95 position patient sample tray, with two separate reagent trays.

Other features of the Pictus 700 include its 72 reagent channels, an independent cooling system, liquid level sensing and clot detection, plus end-point and kinetic detection modes. Unlike many other large floor-standing analyzers, the Pictus 700 possesses a highly efficient cuvette washing system that requires low water consumption (approx. 3 L/hr) and does not need connection to the laboratory plumbing system. The user-friendly software enables strict quality control and an unlimited number of samples can be loaded through the in-built Laboratory Information System (LIS).

As the latest addition to the Pictus family of clinical chemistry analyzers, the high throughput Pictus 700 completes the portfolio, which also includes the benchtop analyzers, Pictus Basic, a simple semi-automated instrument, and medium-throughput automated analyzers, Pictus 200 and Pictus 400.

Diatron recently moved to new, larger and state-of-the-art facilities in Budapest, Hungary, to consolidate production and support of its clinical chemistry and hematology analyzers in one site, allowing the company to respond more quickly to market needs and enhance its R & D efforts.

For more information on the Pictus range and other Diatron products including hematology analyzers, please visit the Diatron Group website: www.diatron.com

The Diatron Group

Diatron’s vision since the company’s foundation in 1989, is to become a worldwide leader in-vitro diagnostics, providing customers with a broad portfolio of high-quality tailored solutions. In its new production facility in Budapest, Hungary, the extensive R&D/Engineering team develops and manufactures compact hematology analyzers and reagents for the human medical and veterinary markets.

Diatron is a portfolio company of, The Riverside Company, a global private equity firm focused on acquiring growing businesses valued at up to $200 million (€200 million in Europe). Founded in 1988, Riverside’s international portfolio now includes 80 companies, and it has more than $3 billion/€2.5 billion in assets under management.

See www.riversidecompany.com for more information


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES